Merus N.V.: Pioneering New Hope in EGFRm NSCLC Treatment while Achieving Impressive Revenue Growth
Merus N.V., a leading clinical-stage immuno-oncology company, recently presented encouraging interim data on its immunotherapy drug MCLA-129 at the prestigious ESMO Asia Congress 2023. The company also reported a remark...
Dec 3, 2023
Clinical Study
Merus
